CompletedNCT00151970
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
This study evaluated the safety and effectiveness of Methylphenidate Transdermal System for people with ADHD.
Medication studyAges 6–12
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Methylphenidate Transdermal System for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 12 years.
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 128
- Sponsor
- Noven Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00151970
- Official title
Show the full official title
A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Methylphenidate Transdermal System for people with ADHD.
Who is behind this study?
The study sponsor is Noven Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate Transdermal System, Placebo and Concerta.
Who was this study for?
Listed age limits: 6 years to 12 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT03785223
Methylphenidate Hydrochloride Controlled Release Capsules for ADHD
Canada
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.